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The ESC Congress will be held in Munich, 25-29/8/2012 
 
TCT Meeting will take place in Miami, 22-26/10/12  
 
HCS Meeting to be held in Athens, 1-3/11/12  
 
AHA 2012 is scheduled for Los Angeles, 3-7/11/12 
  
TWENTE Trial: the Resolute Zotarolimus Eluting 
Stents are Noninferior to Xience V Everolimus 
Eluting Stents in Treating “Real-World” Patients with 
Complex Lesions and “Off-label” Indications for DES 
 
A total of 1,391 patients were randomly assigned to 
zotarolimus eluting stents (ZES) (n = 697) or everolimus 
eluting stents (EES) (n = 694). Acute coronary syndromes 
were present in 52% and “off-label” feature in 77% of 
patients. Of the lesions, 70% were type B2/C; the post-
dilation rate was very high (82%). In ZES and EES, target 
vessel failure (TVF) occurred in 8.2% and 8.1%, 
respectively (absolute risk-difference 0.1%; p 
(noninferiority) = 0.001). The definite-or-probable stent 
thrombosis rates were relatively low and similar for ZES 
and EES (0.9% and 1.2%, respectively, p = NS). Definite 
stent thrombosis rates were also low (0.58% and 0%, 
respectively, p = NS). In EES, probable stent thrombosis 
beyond day 8 was observed only in patients not adhering 
to dual antiplatelet therapy. The authors concluded that 
resolute ZES were noninferior to Xience V EES in 
treating “real-world” patients with a vast majority of 
complex lesions and “off-label” indications for drug-
eluting stents (DES), which were implanted with liberal 
use of post-dilation (von Birgelen C et al, J Am Coll 
Cardiol 2012;59:1350–1361).  
 
The TARGET Study: Placement of the LV Lead to 
the Latest Sites of Contraction and Away from the 
Scar Confers the Best Response to CRT  
 
 Among 220 patients receiving cardiac 
resynchronization therapy (CRT), the left ventricular 
(LV) lead was positioned at the latest site of peak 
contraction (as determined by echocardiographic speckle-
tracking 2-dimensional radial strain imaging) with an 
amplitude of >10% to signify freedom from scar (n=110, 
TARGET group), while in the control group (n=110) 
standard unguided CRT was performed. In the TARGET 
group, there was a greater proportion of responders at 6 
months (70% vs 55%, p = 0.031) with an absolute 
difference in the primary endpoint (>15% reduction in 
LV end-systolic volume at 6 months) of 15%. Compared 
with controls, TARGET patients had a higher clinical 
response (83% vs 65%, p = 0.003) and lower rates of the 
combined endpoint (all-cause mortality and heart failure–
related hospitalization) (p = 0.031). The authors 
concluded that compared with standard CRT treatment, 
the use of speckle-tracking echocardiography to the target 
LV lead placement yields significantly improved 
response and clinical status and lower rates of combined 
death and heart failure–related hospitalization (Khan FZ 
et al, J Am Coll Cardiol 2012;59:1509–1518). 
 
EMPHASIS-HF: In Patients with Systolic Heart 
Failure and Mild Symptoms, Eplerenone Reduced the 
Incidence of New Onset AF/AFlu 
 
Patients in New York Heart Association functional 
class II heart failure (HF) and with ejection fraction 
<35% were eligible for EMPHASIS-HF. New onset atrial 
fibrillation or flutter (AFF) was significantly reduced by 
eplerenone: 25 of 911 (2.7%) vs 40 of 883 (4.5%) in the 
placebo group (hazard ratio -HR: 0.58; p = 0.034). The 
reduction in the primary endpoint (cardiovascular 
mortality or hospitalization for HF) with eplerenone was 
similar among patients with and without AFF at baseline 
(HR: 0.60 vs. HR: 0.70, respectively; p for interaction = 
NS). The primary endpoint, was not significantly 
different in subjects with and without AFF at baseline 
(both study groups combined: HR: 1.23; p = 0.33). The 
authors concluded thatiIn patients with systolic heart 
failure and mild symptoms, eplerenone reduced the 
incidence of new onset AFF. The effects of eplerenone on 
the reduction of major CV events were similar in patients 
with and without AFF at baseline (Swedberg K et al, J 
Am Coll Cardiol 2012;59:1598–1603).  
 
ACUITY Trial: Although Infrequent, Intraprocedural 
Thrombotic Events in Patients Undergoing Early PCI 
for NSTE Acute Coronary Syndrome are Strongly 
Associated with Subsequent Adverse Outcomes  
 
Among 3,428 patients undergoing PCI for non–ST-
segment elevation acute coronary syndrome, an 
intraprocedural thrombotic event (IPTE) (new or 
increasing thrombus, abrupt vessel closure, no reflow, 
slow reflow, or distal embolization) occurred in 121 
patients (3.5%). Patients with IPTE had higher in-
hospital, 30-day, and 1-year major adverse cardiac event 
rates than patients without IPTE (25.6% vs 6.3% in-
hospital, 30.6% vs 9.3% at 30 days, and 37.0% vs. 20.5% 
at 1 year; p <0.0001 for each). An IPTE was strongly 
associated with Q-wave myocardial infarction and stent 
thrombosis (in-hospital 3.3% vs. 0.5%, p = 0.006; 30 
days 5.8% vs. 1.3%, p < 0.0001; and 1 year 6.7% vs. 
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2.0%, p = 0.0002). Unplanned or target vessel 
revascularization, and major bleeding were also increased 
among patients with IPTE, as was overall 30-day 
mortality (3.3% vs. 0.7%, p = 0.002). The authors 
concluded that, although infrequent, IPTE was associated 
with subsequent adverse outcomes including death, 
myocardial infarction, and stent thrombosis (McEntegart 
MB et al, J Am Coll Cardiol 2012;59:1745–1751).  
 
HORIZONS-AMI Trial: Mortality and Major 
Bleeding are Higher After In-hospital Compared with 
Out-of-hospital Stent Thrombosis 
 
Over 3 years, stent thrombosis developed in 156 
(4.9%) of 3,202 STEMI patients receiving stents during 
primary percutaneous coronary intervention (PCI), who 
were randomized to bivalirudin vs unfractionated heparin 
(UFH) plus a glycoprotein IIb/IIIa inhibitor. One year 
after the event of stent thrombosis, patients with in-
hospital (n=54) compared with out-of-hospital (n=102) 
stent thrombosis had significantly greater mortality 
(27.8% vs. 10.8%, p < 0.01); most deaths in both groups 
occurred within 1 week of the thrombotic event. Patients 
with in-hospital stent thrombosis also had higher rates of 
major bleeding (21.2% vs. 6.0%, p < 0.01), but a lower 
rate of myocardial infarction (56.6% vs. 77.5%, p < 0.01). 
Subacute stent thrombosis had the highest mortality. One-
year mortality was significantly increased in patients with 
in-hospital compared with out-of-hospital ST (hazard 
ratio: 4.62, p < 0.01). The authors concluded that 
following primary PCI for STEMI, more than one-third 
of all stent thrombosis events during 3-year follow-up 
occurred during the index hospital phase. Mortality and 
major bleeding were significantly higher after in-hospital 
compared with out-of-hospital stent thrombosis (Dangas 
GD et al, J Am Coll Cardiol 2012;59:1752–1759).  
 
CHARM Program: Resting Heart Rate is an 
Important Predictor of Outcome in Patients with 
Stable Chronic HF without AF, Regardless of LVEF 
or Beta-blocker Use 
 
Patients enrolled in the CHARM heart failure program 
were divided into groups by tertiles of baseline heart rate. 
In the overall population, during a median follow-up of 
37.7 months, 1,831 patients (24.1%) died. Individuals 
with a higher heart rate at baseline had a greater risk of 
death from any cause, compared with those with a lower 
heart rate (p value <0.001). A 10-beat increase in heart 
rate was associated with an 8% increase in the risk of 
death in patients without AF. Patients in the highest heart 
rate tertile had worse outcomes when compared with 
those in the lowest heart rate group. The relationship 
between heart rate and outcomes was similar across 
LVEF categories and was not influenced by beta-blocker 
use. However, amongst patients in AF at baseline, heart 
rate had no predictive value. The authors concluded that 
in patients with stable chronic symptomatic HF and 
without AF, resting heart rate is a powerful predictor of 
mortality and cardiovascular outcomes, irrespective of 
LVEF, treatment with beta-blockers, and other important 
prognostic factors. This easily measured clinical variable 
could be used in the risk stratification of these patients in 
everyday clinical practice (Castagno D et al, J Am Coll 
Cardiol 2012;59:1785–1795).  
 
Cath PCI Registry: Antithrombotic Strategies Have 
Led to a 20% Reduction in Post-PCI Bleeding / 
Adopting the Radial Approoach & Vascular Device 
Closure May Further Promote this Trend 
 
Temporal trends were examined in post-PCI bleeding 
from 2005 to 2009 among patients with elective PCI (n = 
599,524), UA/NSTEMI (n = 836,103), and STEMI (n = 
267,632). An approximate 20% reduction in post-PCI 
bleeding was seen (elective PCI: 1.4% to 1.1%; 
UA/NSTEMI: 2.3% to 1.8; STEMI: 4.9% to 4.5%). 
Radial approach remained low (<3%), and closure device 
use increased marginally from 44% to 49%. Bivalirudin 
use increased (17% to 30%), whereas any heparin + GPI 
decreased (41% to 28%). There was a significant 6% to 
8% per year reduction in annual bleeding risk in 
UA/NSTEMI and elective PCI, but not in STEMI. 
Antithrombotic strategies were associated with roughly 
half of the reduction in annual bleeding risk: change in 
risk ratio from 7.5% to 4% for elective PCI, and 5.7% to 
2.8% for UA/NSTEMI (both p <0.001). The authors 
concluded that the nearly 20% reduction in post-PCI 
bleeding over time was largely due to temporal changes 
in antithrombotic strategies, either an increase in 
bivalirudin use or a decrease in heparin + GPI. Changes 
in vascular access strategies had a smaller impact on the 
change in bleeding risk, likely due to the extremely low 
prevalence of the radial approach and a small increase in 
the use of vascular closure device utilization during the 
study. Temporal bleeding in STEMI did not change 
significantly (Subherwal S et al, J Am Coll Cardiol 
2012;59:1861–1869).  
 
Moderate or Severe Mitral Regurgitation in Patients 
Undergoing TAVI is Associated with a Higher Early, 
but not Late, Mortality Rate  
 
Patients with moderate (n=89) or severe (n=43) mitral 
regurgitation (MR) had a higher mortality rate than those 
with mild or less MR (n=319) during the 30 days after 
transcatheter aortic valve implantation (TAVI) (hazard 
ratio-HR: 2.10; p = 0.02). However, the mortality rates 
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after 30 days were similar (HR: 0.82; p=NS). One year 
after TAVI, moderate MR had improved in 58%, 
remained moderate in 17%, and worsened to severe in 
1%, and 24% of patients had died. Severe MR had 
improved in 49% and remained severe in 16%, and 35% 
of patients had died. Predictors of improved MR at 1 year 
were a mean transaortic gradient >40 mm Hg, functional 
MR, absence of pulmonary hypertension, and absence of 
atrial fibrillation. The authors concluded that moderate or 
severe MR in patients undergoing TAVI is associated 
with a higher early, but not late, mortality rate. At 1-year, 
MR was improved in 55% of patients with moderate or 
severe MR at baseline. Improvement was more likely in 
patients with high transaortic gradients, with functional 
MR, without pulmonary hypertension and without atrial 
fibrillation (Toggweiler S et al, J Am Coll Cardiol 
2012;59:2068–2074).  
 
ADAPT Trial: an Accelerated Diagnostic Protocol 
(ADP) can Successfully Identify Patients at Low 
Short-term Risk of a Cardiac Event and Allow Rapid 
Discharge from the Emergency Department  
 
Among 1975 patients of whom 302 (15.3%) had a 
major cardiac event (MACE), an accelerated diagnostic 
protocol (ADP) which included pre-test probability 
scoring by the TIMI score, ECG, and 0 + 2 h values of 
troponin I, classified 392 patients (20%) as low risk. One 
(0.25%) of these patients had a MACE, giving the ADP a 
sensitivity of 99.7%, negative predictive value of 99.7%, 
specificity of 23.4%, and positive predictive value of 
19.0%. Many ADP negative patients had further 
investigations (74.1%), and therapeutic (18.3%) or 
procedural (2.0%) interventions during the initial hospital 
stay and/or 30-day follow-up. The authors concluded that 
using the ADP, a large group of patients was successfully 
identified as at low short-term risk of a MACE and 
therefore suitable for rapid discharge from the emergency 
room with early follow-up. This approach could decrease 
the observation period required for some patients with 
chest pain (Than M et al, J Am Coll Cardiol 
2012;59:2091–2098).   
 
Post-Conditioning Reduces Infarct Size and Edema 
in Patients With STEMI 
 
In 50 patients with STEMI who were randomly 
assigned to post-conditioning, cardiac magnetic 
resonance imaging was performed within 48-72 h after 
admission to assess myocardial edema and infarct size; 
the latter was also assessed by creatine kinase release. 
Post-conditioning, effected within 1 min of reflow after 
direct stenting, by balloon reinflation (4 times for 1 min 
with low-pressure inflations, each separated by 1 min of 
reflow), was associated with smaller infarct size (p = 
0.01) and creatine kinase peak serum level (p = 0.003). At 
reperfusion, the extent of myocardial edema was 
significantly reduced in the post-conditioned group as 
compared with the control group (p = 0.03). This 
protective effect was confirmed after adjustment for the 
size of the area at risk. The authors concluded that post-
conditioning reduces infarct size and edema in patients 
with reperfused STEMI (Thuny F et al, J Am Coll 
Cardiol 2012;59:2175–2181).  
 
PRODIGY Study: Extended (24-month) Use of Dual-
Antiplatelet Therapy is not More Effective than a 6-
Month Duration of Clopidogrel Followed by Aspirin 
Monotherapy 
 
A total of 2013 patients were randomly assigned to 
receive bare-metal, zotarolimus-eluting, paclitaxel-
eluting, or everolimus-eluting stent implantation. At 30 
days, patients were randomized to receive up to 6 or 24 
months of clopidogrel therapy in addition to aspirin. The 
primary end point was a composite of death of any cause, 
myocardial infarction, or cerebrovascular accident. The 
cumulative risk of the primary outcome at 2 years was 
10.1% with 24-month dual-antiplatelet therapy compared 
with 10.0% with 6-month dual-antiplatelet therapy 
(hazard ratio, 0.98; P=NS). The individual risks of death, 
myocardial infarction, cerebrovascular accident, or stent 
thrombosis did not differ between the study groups; 
however, there was a consistently greater risk of 
hemorrhage in the 24-month clopidogrel group. The 
authors concluded that a regimen of 24 months of 
clopidogrel therapy in patients who receiving a mixture of 
drug-eluting or bare-metal stents was not significantly 
more effective than a 6-month clopidogrel regimen in 
reducing the composite of death due to any cause, 
myocardial infarction, or cerebrovascular accident. 
(Valgimigli M et al, Circulation 2012;125:2015-2026).  
 
Low Incidence of SCD and Low Risk of 
Supraventricular Tachycardia in Asymptomatic 
Patients with Wolff-Parkinson-White ECG Pattern  
 
A total of 20 studies reporting on 1869 asymptomatic 
patients with preexcitation who did not undergo ablation 
were included in this metaanalysis. Participants were 
primarily male (mean age 7 - 43 years). Ten SCDs were 
reported at follow-up. Seven studies originated from Italy 
and reported 9 SCDs. The risk of SCD is estimated at 
1.25 per 1000 person-years. A total of 156 
supraventricular tachycardias were reported involving 
9884 person-years from 18 studies. The risk of 
supraventricular tachycardia was 16 events per 1000 
person-years of follow-up. Children had a bit higher SCD 
28 
 
(1.93 vs 0.86; P=0.07) and supraventricular tachycardia 
(20 vs 14; P=NS) event rates compared with adults. The 
authors of this metaanalysis concluded that there is a low 
incidence of life-threatening arrhythmia in patients with 
asymptomatic preexcitation, which argues against routine 
invasive management in most asymptomatic patients with 
the WPW ECG pattern (Obeyesekere MN et al, 
Circulation 2012;125:2308-2315).  
 
Electronic Control Devices (ECD) (TASER X26) Can 
Cause Cardiac Arrest  
 
The author studied 8 cases of loss of consciousness 
induced by an electronic control device (ECD), TASER 
X26. First recorded rhythms were ventricular tachycardia/ 
fibrillation in 6 cases and asystole (after ~30 minutes of 
nonresponsiveness) in 1 case. An external defibrillator 
reported a shockable rhythm in 1 case, but no recording 
was made. This report offers evidence detailing the 
mechanism by which an ECD can produce transthoracic 
stimulation resulting in cardiac electrical capture and 
ventricular arrhythmias leading to cardiac arrest (Zipes 
DP, Circulation 2012;125:2417-2422).  
 
ACUITY Trial: Incomplete revascularization after 
PCI in Patients with Acute Coronary Syndromes is 
Strongly Associated with 1-year MI, Repeat 
Revascularization, and Major Cardiac Events  
 
Quantitative angiography was performed in 2954 
patients with acute coronary syndromes. With use of 
diameter stenosis cutoffs >30%, >40%, >50%, >60%, and 
>70%, the prevalence of incomplete coronary 
revascularization (ICR) after PCI was 75%, 55%, 37%, 
25%, and 17%, respectively. The 1-year major adverse 
cardiac event (MACE) rate was increased among patients 
with ICR. ICR was associated with higher 1-year rates of 
MI (12.0% vs 8.2%; hazard ratio-HR, 1.50; P=0.0007) 
and ischemia-driven unplanned revascularization (15.7% 
vs 10.2%; HR, 1.58; P<0.0001), with a trend toward 
increased mortality (3.1% vs 2.2%; HR, 1.43; P=0.13). 
By multivariable analysis, ICR was an independent 
predictor of 1-year MACE (HR, 1.36; P=0.002). The 
impact of ICR on MACE was similar regardless of 
chronic total occlusion presence, but it was more 
pronounced with a greater number of nonrevascularized 
lesions. The authors concluded that ICR was strongly 
associated with 1-year myocardial infarction, ischemia-
driven unplanned revascularization, and MACE (Rosner 
GF et al, (Circulation. 2012;125:2613-2620).  
 
ISSUE-3 Trial: 15% of Patients with Severe Asystolic 
Neurally Mediated Syncope Fulfilled the Criteria for a 
Pacemaker which Reduced Recurrences by 57% 
 
Initially, 511 patients, >40 years, who had experienced 
>3 syncopal episodes in the previous 2 years, received an 
implantable loop recorder (ILR); 89 of these had 
documentation of syncope with >3 s asystole or >6 s 
asystole without syncope and met criteria for pacemaker 
implantation; 77 of 89 patients were randomly assigned to 
dual-chamber pacing with rate drop response or to 
sensing only. Syncope recurred in 27 patients, 19 of 
whom had been assigned to pacemaker OFF and 8 to 
pacemaker ON. The 2-year estimated syncope recurrence 
rate was 57% with pacemaker OFF and 25% with 
pacemaker ON (1P=0.039). The risk of recurrence was 
reduced by 57%. Complications occurred in 5 patients: 
lead dislodgment (n=4) and subclavian vein thrombosis 
(n=1). The authors concluded that dual-chamber 
permanent pacing is effective in reducing (by 57%) 
recurrence of syncope in patients >40 years with severe 
asystolic neurally mediated syncope (Brignole M et al, 
Circulation 2012;125:2566-2571).  
 
ROOBY Trial: Off-Pump CABG is Associated With 
Worse Arterial and Saphenous Vein Graft Patency 
and Less Effective Revascularization 
 
A total of 2203 patients were randomized to off-pump 
vs on-pump coronary bypass (CABG) (2/2002-5/2007). 
Follow-up angiograms were obtained in 685 off-pump 
(62%) and 685 on-pump (62%) patients and were 
analyzed for FitzGibbon classification (A=widely patent, 
B=flow limited, O=occluded) and effective 
revascularization (all 3 diseased major coronaries with 
significant disease revascularized by FitzGibbon A-
quality, with no new postanastomotic lesions). Off-pump 
CABG resulted in lower FitzGibbon A patency rates than 
on-pump CABG for arterial conduits (85.8% vs 91.4%; 
P=0.003) and saphenous vein grafts (72.7% vs 80.4%; 
P<0.001). Fewer off-pump patients were effectively 
revascularized (50.1% vs 63.9% on-pump; P<0.001). The 
1-year adverse cardiac event rate was 16.4% in patients 
with ineffective revascularization vs 5.9% in patients with 
effective revascularization (P<0.001). The authors 
concluded that off-pump CABG resulted in significantly 
lower FitzGibbon A graft patency and less effective 
revascularization than on-pump CABG. At 1 year, 
patients with less effective revascularization had higher 
adverse event rates (Hattler B et al, Circulation 
2012;125:2827-2835).  
 
Drug Eluting Stents (DES) are Highly Efficacious at 
Reducing Short- and Long-Term Risk of Target 
Vessel Revascularization without an Increase in any 
Safety Outcomes, Including Stent Thrombosis, 
Compared with BMS  
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Analysis of 76 trials enrolling 57,138 patients showed 
that compared with bare metal stents (BMS), each drug-
eluting stent (DES) reduced long-term target-vessel 
revascularization (39%–61%), but the magnitude varied 
by DES type (everolimus eluting-EES~sirolimus eluting-
SES~zotarolimus eluting Resolute-ZES-R>paclitaxel 
eluting-PES~ZES>BMS), with a >42% probability that 
EES had the lowest target-vessel revascularization rate. 
There was no increase in the risk of any long-term safety 
outcomes, including stent thrombosis, with any DES (vs 
BMS). There was also reduction in MI (all DES except 
PES vs BMS) and stent thrombosis (with EES vs BMS). 
The safest DES appeared to be EES (>86% probability), 
with reduction in MI and stent thrombosis compared with 
BMS. Short-term outcomes were similar to long-term 
outcomes, with SES, ZES-R, and EES being the most 
efficacious and EES being the safest stent. The authors 
concluded that DES are highly efficacious at reducing the 
risk of target-vessel revascularization without an increase 
in any safety outcomes, including stent thrombosis, 
compared with BMS. However, among the DES types, 
there were considerable differences, such that EES, SES, 
and ZES-R were the most effective and EES was the 
safest stent in terms of stent thrombosis (Bangalore S et 
al, Circulation 2012;125:2873-2891).  
 
PLATO Trial: Treatment with Ticagrelor should not 
be Withheld in Acute Coronary Syndrome Patients 
with a History of Ischemic Stroke or TIA for Safety 
Concerns if Otherwise Indicated  
 
Treatment effects of ticagrelor vs clopidogrel were 
evaluated n patients with acute coronary syndrome with 
and without a history of prior stroke or TIA in the 
PLATO trial. Of the 18,624 randomized patients, 1152 
(6.2%) had a history of stroke or TIA. Such patients had 
higher rates of MI (11.5% vs 6.0%), death (10.5% vs 
4.9%), stroke (3.4% vs 1.2%), and intracranial bleeding 
(0.8% vs 0.2%) than patients without prior stroke or TIA. 
However, the reduction of the primary composite 
outcome and total mortality at 1 year with ticagrelor vs 
clopidogrel was consistent with the overall trial results: 
19.0% vs 20.8% (hazard ratio-HR, 0.87; P=NS) and 7.9% 
vs 13.0% (HR, 0.62). The overall PLATO-defined 
bleeding rates were similar: 14.6% vs 14.9% (HR, 0.99), 
and intracranial bleeding occurred only in 4 cases in each 
group. The authors concluded that patients with acute 
coronary syndrome with a prior history of ischemic stroke 
or TIA had higher rates of clinical outcomes than patients 
without prior stroke or TIA. However, the efficacy and 
bleeding results of ticagrelor in these high-risk patients 
were consistent with the overall trial population, with a 
favorable clinical net benefit (James SK et al, Circulation 
2012;125:2914-2921).  
 
Early Surgery in Patients With Infective Endocarditis 
and Large Vegetations Significantly Reduced 
Mortality and Embolic Events 
 
Patients with left-sided infective endocarditis, severe 
valve disease, and large vegetations were randomized to 
early (within 48 h) surgery (n=37) or conventional 
treatment (n=39); with 30 patients (77%) of the latter 
group finally having surgery during initial hospitalization 
(n=27) or during follow-up (n=3). The primary end point 
(in-hospital death and embolic events) occurred in 1 
patient (3%) in the earlysurgery group as compared with 
9 (23%) in the conventional-treatment group (hazard 
ratio-HR, 0.10; P = 0.03). The rate of the composite end 
point of death from any cause, embolic events, or 
recurrence of infective endocarditis at 6 months was 3% 
in the early-surgery group and 28% in the conventional-
treatment group (HR, 0.08; P = 0.02). The authors 
concluded that early surgery in patients with infective 
endocarditis and large vegetations significantly reduced 
the composite end point of death from any cause and 
embolic events (Kang D et al, N Engl J Med 
2012;366:2466-2473). 
 
Important Review and Other Articles  
 
New oral anticoagulants in AF & ACS (De Caterina R 
et al, J Am Coll Cardiol 2012; 59:1413-1425), PFO 
(Kutty S et al, J Am Coll Cardiol 2012;59:1665-1671), 
Ventricular arrhythmias in normal heart (Prystowsky EN 
et al, J Am Coll Cardiol 2012;59:1733-1744), 
Appropriateness of coronary revascularization for 
patients without ACS (Hannan EL et al, J Am Coll 
Cardiol 2012;59:1870-1876), 2012 Appropriate use 
criteria for diagnostic catheterization (Patel MR et al, J 
Am Coll Cardiol 2012;59:1-33), Expert consensus 
statement for TAVI (Tommaso CL et al, J Am Coll 
Cardiol 2012;59:2028-2042), Sudden cardiac death and 
genetic ion channelopathies (Napolitano C et al, 
Circulation 2012;125:2027-2034), Sudden cardiac death 
in the athlete (Link & Estes, Circulation 2012;125:2512-
2516), Thrombolytic therapy of acute stroke (Feske SK, 
Circulation 2012;125:2662-2666), Antithrombotic 
therapy in patients with chronic kidney disease 
(Capodanno & Angiolillo, Circulation 2012;125:2649-
2661), Bleeding and thrombosis in patients with 
continuous-flow ventricular assist devices (Eckman & 
John, Circulation 2012;125:3038-3047), Genetics & 
cardiovascular disease (Ashley EA et al, Circulation 
2012;126:142-157), VT ablation (Wissner E et al, Eur 
Heart J 2012; 33:1440-1450).  
